Annual report pursuant to Section 13 and 15(d)

Note 3 - Supplemental Balance Sheet and Cash Flow Information

v3.19.3
Note 3 - Supplemental Balance Sheet and Cash Flow Information
12 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]
Note
3.
Supplemental Balance Sheet and Cash Flow Information:
 
Available-For-Sale Investments:
 
The fair value of the Company's available-for-sale investments as of
June 30, 2019
and
June 30, 2018
were
$38.2
million and
$54.3
million, respectively. The decrease was due
to year-over-year decreases in the stock price of CCXI, from
$13.17
per share at
June 30, 2018 
to
$9.30
per share at
June 30, 2019
resulting in a
$16.1
million decrease in the fair value of the Company's investment in CCXI. The amortized cost basis of the Company's investment in CCXI was 
$18.8
million as of
June 30, 2019
and
2018.
 
Inventories:
 
Inventories consist of (in thousands):
 
   
June 30,
 
   
2019
   
201
8
 
                 
Raw materials
  $
40,913
    $
30,956
 
Finished goods
(1)
   
53,376
     
54,692
 
Inventories, net
  $
94,289
    $
85,648
 
 
(
1
) Finished goods inventory of
$3,239
is included within other long-term assets in the
June 30, 2019
Balance Sheet as it forecasted to be sold after the
12
months subsequent to the consolidated balance sheet date.  
 
Property and Equipment:
 
Property and equipment consist of (in thousands):
 
   
June 30,
 
   
201
9
   
201
8
 
Cost:
               
Land
  $
7,065
    $
7,065
 
Buildings and improvements
   
175,019
     
170,110
 
Machinery, equipment and other
   
124,233
     
107,625
 
Property and equipment
   
306,317
     
284,800
 
Accumulated depreciation and amortization
   
(152,278
)
   
(139,452
)
Property and equipment, net
  $
154,039
    $
145,348
 
 
Intangibles assets were comprised of the following (in thousands):
 
   
 
 
 
 
 
June 30,
 
   
Useful Life
(years)
   
201
9
   
201
8
 
                           
Developed technology
 
9
-
15
    $
435,679
    $
305,303
 
Trade names
 
2
-
20
     
147,296
     
89,608
 
Customer relationships
 
7
-
16
     
214,320
     
212,228
 
Patents
 
 
10
 
     
2,133
     
1,401
 
Intangible assets
 
 
 
 
     
799,428
     
608,540
 
Accumulated amortization
 
 
 
 
     
(219,999
)
   
(162,208
)
Intangibles assets, net
 
 
 
 
    $
579,429
    $
446,332
 
 
Changes to the carrying amount of net intangible assets consist of (in thousands):
 
   
June 30,
 
   
201
9
   
201
8
 
                 
Beginning balance
  $
446,332
    $
452,042
 
Acquisitions (Note 4)
   
191,956
     
40,673
 
Other additions
   
633
     
908
 
Amortization expense
   
(58,715
)
   
(47,076
)
Currency translation
   
(777
)
   
(215
)
Ending balance
  $
579,429
    $
446,332
 
 
Amortization expense related to technologies included in cost of sales was
$33.3
 million,
$25.3
million, and
$23.1
million in fiscal
2019,
2018,
and
2017,
respectively. Amortization expense related to trade names, customer relationships, non-compete agreements, and patents included in selling, general and administrative expense was
$25.4
 million,
$21.6
million, and
$21.3
million, in fiscal
2019,
2018,
and
2017
respectively.
 
The estimated future amortization expense for intangible assets as of
June 30, 2019
is as follows (in thousands):
 
2020
  $
59,905
 
2021
   
59,557
 
2022
   
57,905
 
2023
   
56,031
 
2024
   
53,464
 
Thereafter
   
292,567
 
Total
  $
579,429
 
 
Changes in goodwill by reportable segment and in total consist of (in thousands):
 
   
Protein
Sciences
   
Diagnostics &
Genomics
   
Total
 
June 30, 2017
  $
331,789
    $
247,237
    $
579,026
 
Acquisitions (Note 4)
   
16,186
     
2,910
     
19,096
 
Currency translation
   
(56
)
   
(176
)    
(232
)
June 30, 2018
  $
347,918
    $
249,972
    $
597,890
 
Acquisitions (Note 4)
   
30,939
     
105,362
     
136,301
 
Currency translation
   
(1,450
)    
(74
)    
(1,524
)
June 30, 2019
  $
377,407
    $
355,260
    $
732,667
 
 
Other Assets:
 
Other assets consist of (in thousands):
 
   
June 30,
 
   
201
9
   
201
8
 
                 
Investments
  $
-
    $
2,606
 
Other
   
5,668
     
2,660
 
Other long-term assets
  $
5,668
    $
5,266
 
 
 
As of
June 30, 2019,
the Company had
$5.7
 million of other assets compared to
$5.3
million as of
June 30, 2018. 
The increase was attributable to finished goods inventory of
$3.2
million included within other long-term assets in the
June 30, 2019
Balance Sheet as it forecasted to be sold after the
12
months subsequent to the consolidated balance sheet date. This increase was partially offset by the reduction in investments related to our purchase of the outstanding shares of B-MoGen discussed in note
4
and the reclassification of the amounts held in escrow from our Astute investment classified as a long-term asset as of
June 30, 2018 
to a short-term asset as of
June 30, 2019
as we are expected to receive the final proceeds within the next
12
months. 
 
Supplemental Cash Flow Information:
 
Supplemental cash flow information was as follows (in thousands):
 
   
Year Ended June 30,
 
   
201
9
   
201
8
   
201
7
 
Income taxes paid
  $
36,814
    $
35,076
    $
42,900
 
Interest paid
   
21,497
     
9,844
     
7,452
 
Non-cash activities:
                       
Acquisition-related liabilities
(1)
   
12,600
     
1,396
     
32,856
 
 
 
(
1
)
Consists of holdback payments due at future dates and liabilities for contingent consideration. Further information regarding liabilities for contingent consideration can be found in Notes 
4
and
5.